Clinical Trial Update: Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes that EX103 is being studied in a Phase 1/2 trial for relapsed or refractory CD20-positive non-Hodgkin lymphoma and is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• EX103

Snippet

Sponsor: Guangzhou Excelmab Inc. | Conditions: CD20-positive Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING